Inefficient ubiquitination of ligand-responsive p-6Y-EGFR mutants by p-Y371-CBL

Stable Identifier
Reaction [transition]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Phosphorylated CBL does not ubiquitinate EGFR kinase domain mutants efficiently, which enables mutant proteins to escape degradation. There are indications that phosphorylated CBL shows decreased affinity for EGFR kinase domain mutants compared to wild-type EGFR proteins, and quickly dissociates, before ubiquitination is completed. This decreased affinity may be due to altered structure of EGFR kinase domain mutants or to the presence of the chaperone protein HSP90 in complex with the mutant protein. Weaker afinity for phosphorylated CBL was directly demonstrated for EGFR L858R mutant (Yang et al. 2006), and poor ubiquitination inspite of CBL binding was shown for EGFR L858R and EGFR E746_A750del mutants (Yang et al. 2006, Padron et al. 2007).

Literature References
PubMed ID Title Journal Year
16849543 Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors

Yang, S, Qu, S, Perez-Tores, M, Sawai, A, Rosen, N, Solit, DB, Arteaga, CL

Cancer Res 2006
17699773 Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized

PadrĂ³n, D, Sato, M, Shay, JW, Gazdar, AF, Minna, JD, Roth, MG

Cancer Res 2007
Participant Of
Catalyst Activity
Catalyst Activity
ubiquitin protein ligase activity of Ligand-responsive p-6Y-EGFR mutants:p-Y371-CBL [plasma membrane]
Physical Entity
This event is regulated
Normal reaction
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!